Lack of a pharmacokinetic effect between steady-state tipranavir/ritonavir (TPV/r) and single-dose valacyclovir in healthy volunteers.

**ABSTRACT**

**Introduction:** Tipranavir (TPV) is a novel generation protease inhibitor (PI) with potent activity against the majority of HIV-1 strains. This study was conducted to assess the impact of TPV on the pharmacokinetics (PK) of acyclovir (ACV) in healthy volunteers. TPV is known to have potential for drug-drug interactions (DDIs) with a number of PI-boosted regimens. A co-administration of TPV/r500/200mg bid with single-dose ACV600mg in healthy volunteers. This study is important to establish the drug-drug interaction potential for these medications.

**Methods:** This was a randomized, double-blind, placebo-controlled, one-way crossover study. Subjects were randomized to receive placebo or TPV/r500/200mg twice-daily for 14 days. At steady state, a single-dose 600-mg dose of ACV was administered, and TPV r/r500/200 mg and single-dose VAL 500 mg in healthy female and male volunteers. Figure 1: Valacyclovir drug-drug interaction study design. Table 1: Demographics and baseline characteristics of the study population. Table 2: Effect of steady-state TPV/r 500/200 mg on the single-dose pharmacokinetics of acyclovir. Table 3: Effect of single-dose VAL 500 mg in the steady-state pharmacokinetics of TPV r 500/200 mg. Table 4: Effect of single-dose VAL 500 mg in the steady-state pharmacokinetics of TPV r 500/200 mg.

**Results:** Twenty-six of 29 subjects completed the trial. With steady-state TPV/r 500/200 mg, ACV Cmax decreased 4.9% [0.95, 0.88–1.02], Cmax 12 h increased 18.9% [1.19, 1.11–1.27] and AUC inf increased 29.3% [0.99, 0.88–1.07].

**Conclusions:** In conclusion, for the majority of AEs reported, no trend towards the values reported in the VALTREX® product label [2] (mean ± SD Cmax, CL/F, t1/2) was observed. TPV r/r500/200 mg and single-dose VAL 500 mg were comparable to the values reported in the VALTREX® product label [2] (mean ± SD Cmax, CL/F, t1/2).

**References:** 1. Malee, Y., Bako, S., Amsler, H., Schöttler, L., McClure, S., Pharmaceuticals, Inc., 2005. 2. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; Boehringer Ingelheim Spain, Santi Cuadet del Valle, Spain; HVI Specialized Practice, Düsseldorf, Germany.